December 4, 2023

A new drug is making headlines after multiple studies found it led to dramatic weight loss and a significant reduction in A1C, or average blood sugar levels, in people with type 2 diabetes.

Called tirzepatide and marketed as Mounjaro, the drug was approved by the U.S. Food and Drug Administration (FDA) as a new class of medication for people with type 2 diabetes on May 13, 2022. Now, some health experts are speculating that the drug may hold potential as a treatment for obesity in people without diabetes as well. Many people who manage and treat type 2 diabetes are waiting to hear more about that prospect from the upcoming American Diabetes Association (ADA) Scientific Sessions, the organization’s annual meeting being held June 3 to 7, 2022.

“It was very exciting to hear that this became approved,” says Robert Gabbay, MD, PhD, chief science and medical officer for the ADA, in Arlington, Virginia. “Last year at this time, in our scientific sessions, studies were presented and simultaneously published in The New England Journal of Medicine that led to its approval. Now to have tirzepatide available both clinicians and patients are, to some degree, chomping at the bit to have these kind of benefits.”

Although the once-weekly injection is not yet available, its drugmaker Eli Lilly expects its launch in the coming weeks.


Leave a Reply

Your email address will not be published. Required fields are marked *